Skip to main content
Clinical Trials/DRKS00030597
DRKS00030597
Recruiting
Not Applicable

Metabolic health in neurodegenerative diseases - implications of metabolic characteristics and gut microbiome - NeuroBiom

Klinik und Poliklinik für Neurologie, Universitätsklinikum Bonn0 sites100 target enrollmentFebruary 7, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
G20
Sponsor
Klinik und Poliklinik für Neurologie, Universitätsklinikum Bonn
Enrollment
100
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 7, 2023
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Klinik und Poliklinik für Neurologie, Universitätsklinikum Bonn

Eligibility Criteria

Inclusion Criteria

  • BMI 18,5\-39,9 kg/m²
  • Non\-smoker (for at least 3 months)
  • written declaration of consent for participation in the study.
  • Diagnosis Parkinson disease or Alzheimer disease
  • PD based on clinical diagnosis according to Brain Bank criteria(Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. A clinico\-pathological study of 100 cases. JNNP 1992;55:181\-184\.)
  • Hoehn \& Yahr stadium 1\-3
  • Clinical and biomarker\-based diagnosis with Alzheimer's pathology based on typical CSF findings
  • Mixed dementia with a vascular component (up to Fazekas II) is permitted.

Exclusion Criteria

  • Taking medications that affect glucose metabolism
  • chronic hepatic diseases, gastrointestinal diseases, chronic inflammatory diseases or other severe diseases
  • antibiotic therapy 3 weeks before the start of the study
  • Planned lifestyle changes
  • regular intake of supplements
  • drug abuse
  • participation in another clinical trial simultaneously/in the last 30 days
  • Atypical PD syndromes
  • severe motor fluctuations
  • Dementia of unclear origin

Outcomes

Primary Outcomes

Not specified

Similar Trials